

890 West Pender Street, Suite 600  
Vancouver, British Columbia  
Canada V6C 1J9  
778-998-5000



69 Longwood Avenue  
Hyannis Port, MA, 02647 USA  
617-571-6006  
[www.imaginmedical.com](http://www.imaginmedical.com)

CSE Symbol: IME  
OTC Pink Symbol: IMEXF  
Frankfurt/Stuttgart Stock Exchange: DPD2

NR-2017-IME - 26

## IMAGIN MEDICAL INVESTORS EXERCISE WARRANTS GENERATING \$1M

*Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care for urologists in detecting cancers and visualizing the surgical field in minimally invasive surgery. The Company's initial focus is bladder cancer.*

**Vancouver, B.C. and Boston, MA,** December 8, 2017 – Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (the “Company”) announced today that the Company has received more than \$1M through the exercising of warrants by long-term investors.

In the two months since the University of Rochester approved the first in-human research study using the i/Blue Imaging System and opened the study for enrollment, Imagin stock has realized significant price and volume growth. Demonstrating confidence in the Company’s direction, many of Imagin’s investors have exercised \$0.12 and \$0.15 warrants, generating over \$1M of capital. The support of these shareholders places the Company in a stronger financial position heading into 2018 and the start of the study.

Imagin is also reporting that the recent sale of 75,000 shares by a Director to support the company by exercising warrants was erroneously recorded on an “insider trading” report as 775,000 shares. This report has been corrected.

### **About Imagin Medical**

*Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at [www.imaginmedical.com](http://www.imaginmedical.com).*

### **For further information, contact:**

Jim Hutchens, President & CEO  
Telephone: 617-571-6006  
Email: [jhutchens@imaginmedical.com](mailto:jhutchens@imaginmedical.com)

*Information set forth in this news release contains forward-looking statements. These statements reflect management's current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company's imaging system will work in the manner expected, except as required under applicable securities legislation; the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.*